| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.3 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.066 | 0.3 |
| mRNA | VX-680 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.3 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.041 | 0.3 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.047 | 0.3 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.065 | 0.3 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.044 | 0.3 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.045 | 0.3 |